Impact of pemafibrate in patients with metabolic dysfunction-associated steatotic liver disease complicated by dyslipidemia: A single-arm prospective study.

Hiroki OnoMasanori AtsukawaAkihito TsubotaTaeang AraiKenta SuzukiTetsuyuki HigashiMichika KitamuraKaori Shioda-KoyanoTadamichi KawanoYuji YoshidaTomomi OkuboKorenobu HayamaNorio ItokawaChisa KondoMototsugu NagaoMasato IwabuKatsuhiko Iwakiri

Published in: JGH open : an open access journal of gastroenterology and hepatology (2024)

This study demonstrated that 48-week pemafibrate administration improved liver-related enzymes and surrogate marker of liver fibrosis in patients with MASLD. The improvement of insulin resistance by pemafibrate may contribute to the favorable effect on MASLD complicated by dyslipidemia.

Keyphrases

liver fibrosis
insulin resistance
type diabetes
adipose tissue
metabolic syndrome
high fat diet
polycystic ovary syndrome
randomized controlled trial
clinical trial
glycemic control